April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Antiangiogenic Therapy In The Treatment For Retinopathy Of Prematurity, Four Years Follow Up. What We Have Learned.
Author Affiliations & Notes
  • M. A. Martinez-Castellanos
    Retina and Vitreous, Association Para Evitar la Ceguera, Mexico, Mexico
  • H. Quiroz-Mercado
    Denver Health Medical Center, Denver, Colorado
  • J. Guerrero-Naranjo
    Retina, Asoc Para Evitar la Ceguera en Mexico, Mexico City, Mexico
  • G. Garcia-Aguirre
    Retina, Asoc Para Evitar la Ceguera, Mexico City, Mexico
  • R. V. Chan
    Ophthalmology, Weill Cornell Medical College, New York, New York
  • Footnotes
    Commercial Relationships  M.A. Martinez-Castellanos, None; H. Quiroz-Mercado, None; J. Guerrero-Naranjo, None; G. Garcia-Aguirre, None; R.V. Chan, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5294. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. A. Martinez-Castellanos, H. Quiroz-Mercado, J. Guerrero-Naranjo, G. Garcia-Aguirre, R. V. Chan; Antiangiogenic Therapy In The Treatment For Retinopathy Of Prematurity, Four Years Follow Up. What We Have Learned.. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5294.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To report our findings after a four years follow-up study, in a group of infants treated with antiangiogenic therapy for retinopathy of prematurity a few weeks after birth

Methods: : We performed a prospective, logitudinal follow-up study in premature patients with stage III, thereshold, prethereshold, plus disease and IVa few weeks after birth. Neovascular regression, anatomical findings, functional test, neurodevelopmental outcome, refraction and antropometric measurements were recorded.

Results: : We included 18 eyes of 13 patients, we found neovascular regression in all of the patients, normal vasculature growth in the ones that had stage III, pre thereshold, thereshold and plus disease, one psatient in IVa presented spontaneous retina attachement, we found no abnormalities in neurodevelopment and antropometric measurements, retina function was conserved 4 years after the injection, assesed by ERG , refraction and visual accuity, We found prevalence of myopia in treated patients

Conclusions: : Antiangiogenic therapy as a treatment for retinopathy of prematury seems to be a safe and effective therapy at a 4 years follow up in this small series. This study may move us closer to a better treatment to this devastating disease

Clinical Trial: : www.clinicaltrials.gov NCT00346814

Keywords: retinopathy of prematurity • clinical (human) or epidemiologic studies: outcomes/complications • infant vision 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.